Human scFv SIgA expressed on Lactococcus lactis as a vector for the treatment of mucosal disease

Molecular Nutrition and Food Research

Volumn 52, Issue 8, 2008, Pages 913-920

  Yuvaraj, Saravanan ^a   Lahham, Saed ^a   Marreddy, Ravi K R ^b   Dijkstra, Gerard ^a   Wolken, Wout A M ^b   Lolkema, Juke S ^b   Helfrich, Wijnand ^a   Johansen, Finn Erik ^c   Peppelenbosch, Maikel P ^a   Bos, Nicolaas A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Lactococcus lactis; Local delivery system; pIgR; Recombinant; scFv SIgA

Indexed keywords

BACTERIA (MICROORGANISMS); LACTOCOCCUS LACTIS;

IMMUNOGLOBULIN FRAGMENT; IMMUNOGLOBULIN FV; SECRETORY IMMUNOGLOBULIN;

ANIMAL; ARTICLE; CELL STRAIN COS1; CERCOPITHECUS; COLON TUMOR; GENE THERAPY; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; HUMAN; LACTOCOCCUS LACTIS; LEUKEMIA CELL LINE;

ANIMALS; CERCOPITHECUS AETHIOPS; COLONIC NEOPLASMS; COS CELLS; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOGLOBULIN A, SECRETORY; IMMUNOGLOBULIN FRAGMENTS; JURKAT CELLS; LACTOCOCCUS LACTIS; TRANSFECTION;

EID: 54549084322     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.200700132     Document Type: Article

References (30)

1. Braat, H., Peppelenbosch, M. P., Hommes, D. W., Immunology of Crohn's disease. Ann. N. Y. Acad. Sci. 2006, 1072, 135-154.
2. Vogelstein, B., Kinzler, K. W., Cancer genes and the pathways they control. Nat. Med. 2004, 10, 789-799.
3. Van den Brande, J. M., Koehler, T., Zelinkova, Z., Bennink, R. J., et al., Prediction of anti-TNF clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Gut 2007, 56, 509-517.
4. Brandtzaeg, P., Farstad, I. N., Johansen, F. E., Morton, H. C., et al., The B-cell system of human mucosae and exocrine glands. Immunol. Rev. 1999, 171, 45-87.
5. Johansen, F. E., Brandtzaeg, P., Transcriptional regulation of the mucosal IgA system. Trends Immunol. 2004, 25, 150-157.
6. Kanamaru, Y., Tamouza, H., Pfirsch, S., El Mehdi, D., et al., IgA Fc receptor I signals apoptosis through the FcR{gamma} ITAM and affects tumor growth. Blood 2007, 109, 203-211.
7. Valerius, T., Stockmeyer, B., van Spriel, A. B., Graziano, R. F., et al., FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy. Blood 1997, 90, 4485-4492.
8. Huls, G., Heijnen, I. A., Cuomo, E., van der, L. J., et al., Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies. Cancer Res. 1999, 59, 5778-5784.
9. Glennie, M. J., Johnson, P. W., Clinical trials of antibody therapy. Immunol. Today 2000, 21, 403-410.
10. Alvarez, R. D., Barnes, M. N., Gomez-Navarro, J., Wang, M., et al., A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): A phase I trial. Clin. Cancer Res. 2000, 6, 3081-3087.
11. Balzar, M., Winter, M. J., de Boer, C. J., Litvinov, S. V., The biology of the 17-1A antigen (Ep-CAM). J. Mol. Med. 1999, 77, 699-712.
12. Moldenhauer, G., Momburg, F., Moller, P., Schwartz, R., Hammerling, G. J., Epithelium-specific surface glycoprotein of Mr 34,000 is a widely distributed human carcinoma marker. Br. J. Cancer 1987, 56, 714-721.
13. Helfrich, W., Kroesen, B. J., Roovers, R. C., Westers, L., et al., Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas. Int. J. Cancer 1998, 76, 232-239.
14. Bremer, E., Samplonius, D., Kroesen, B. J., van Genne, L., et al., Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells. Neoplasia 2004, 6, 636-645.
15. Bremer, E., Ten Cate, B., Samplonius, D. F., de Leij, L. F., Helfrich, W., CD7-restricted activation of Fas-mediated apoptosis: A novel therapeutic approach for acute T-cell leukemia. Blood 2006, 107, 2863-70.
16. Ragnhammar, P., Fagerberg, J., Frodin, J. E., Hjelm, A. L., et al., Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma-long-lasting, complete remissions can be induced. Int. J. Cancer 1993, 53, 751-758.
17. Ragnhammar, P., Magnusson, I., Masucci, G., Mellstedt, H., The therapeutic use of the unconjugated monoclonal antibodies (MAb) 17-1A in combination with GM-CSF in the treatment of colorectal carcinoma (CRC). Med. Oncol. Tumor Pharmacother. 1993, 10, 61-70.
18. Riethmuller, G., Holz, E., Schlimok, G., Schmiegel, W., et al., Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial. J. Clin. Oncol. 1998, 16, 1788-1794.
19. Braat, H., Rottiers, P., Hommes, D. W., Huyghebaert, N., et al., A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin. Gastroenterol. Hepatol. 2006, 4, 754-759.
20. Schjerven, H., Brandtzaeg, P., Johansen, F. E., A novel NF-kappa B/Rel site in intron 1 cooperates with proximal promoter elements to mediate TNF-alpha-induced transcription of the human polymeric Ig receptor. J. Immunol. 2001, 167, 6412-6420.
21. Bandell, M., Lolkema, J. S., The conserved C-terminus of the citrate (CitP) and malate (MleP) transporters of lactic acid bacteria is involved in substrate recognition. Biochemistry 2000, 39, 13059-13067.
22. Holo, H., Nes, I. F., High-frequency transformation, by electroporation, of Lactococcus lactis subsp. cremoris grown with glycine in osmotically stabilized media. Appl. Environ. Microbiol. 1989, 55, 3119-3123.
23. de Ruyter, P. G., Kuipers, O. P., de Vos, W. M., Controlled gene expression systems for Lactococcus lactis with the food-grade inducer nisin. Appl. Environ. Microbiol. 1996, 62, 3662-3667.
24. Guikema, J. E., Vellenga, E., Veeneman, J. M., Hovenga, S., et al., Multiple myeloma related cells in patients undergoing autologous peripheral blood stem cell transplantation. Br. J. Haematol. 1999, 104, 748-754.
25. Elm, C., Braathen, R., Bergmann, S., Frank, R., et al., Ectodomains 3 and 4 of human polymeric Immunoglobulin receptor (hpIgR) mediate invasion of Streptococcus pneumoniae into the epithelium. J. Biol. Chem. 2004, 279, 6296-6304.
26. Almogren, A., Senior, B. W., Kerr, M. A., A comparison of the binding of secretory component to immunoglobulin A (IgA) in human colostral S-IgA1 and S-IgA2. Immunology 2006, 120, 273-280.
27. Withoff, S., Helfrich, W., de Leij, L. F., Molema, G., Bi-specific antibody therapy for the treatment of cancer. Curr. Opin. Mol. Ther. 2001, 3, 53-62.
28. Schaedel, O., Reiter, Y., Antibodies and their fragments as anti-cancer agents. Curr. Pharm. Des. 2006, 12, 363-378.
29. Gomes, M. M., Herr, A. B., IgA and IgA-specific receptors in human disease: Structural and functional insights into pathogenesis and therapeutic potential. Springer Semin. Immunopathol. 2006, 28, 383-395.
30. Yuvaraj, S., Peppelenbosch, M. P., Bos, N. A., Transgenic probiotica as drug delivery systems: The golden bullet? Expert Opin. Drug Deliv. 2007, 4, 1-3.